Immune and pathologic responses in patients with localized prostate cancer who received daratumumab (anti-CD38) or edicotinib (CSF-1R inhibitor)
Bilal A. Siddiqui, Brian F. Chapin, Sonali Jindal, Fei Duan, Sreyashi Basu, Shalini S. Yadav, Ai Di Gu, Alexsandra B. Espejo, Michelle Kinder, Curtis A. Pettaway, John F. Ward, Rebecca S.S. Tidwell, Patricia Troncoso, Paul G. Corn, Christopher J. Logothetis, Roland Knoblauch, Natalie Hutnick, Marco Gottardis, Charles G. Drake, Padmanee SharmaSumit K. Subudhi
Research output: Contribution to journal › Article › peer-review
Dive into the research topics of 'Immune and pathologic responses in patients with localized prostate cancer who received daratumumab (anti-CD38) or edicotinib (CSF-1R inhibitor)'. Together they form a unique fingerprint.